BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors
Abstract Aberrant activation of tropomyosin receptor kinases (TRKs) is a well-defined oncogenic driver for neurotrophic tropomyosin receptor kinase (NTRK)-fusion cancers, and acquired resistant mutations have emerged with clinical use of the first-generation TRK inhibitors. Here we present BPI-28592...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Portfolio
2024-09-01
|
| coleção: | npj Precision Oncology |
| Acesso em linha: | https://doi.org/10.1038/s41698-024-00686-8 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|